Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Peter Shcherbakov"'
Autor:
Thomas Casswall, Patrick Bontems, Maria José Martinez-Gomez, Samy Cadranel, Sibylle Koletzko, Francis Mégraud, Petronella E. C. Mourad-Baars, Giuseppina Oderda, Frédéric Gottrand, Sonny K. F. Chong, Thierry Lamireau, Nicolas Kalach, Vibeke Wewer, Eleftheria Roma-Giannikou, Barbara Iwańczak, Gábor Veres, Josef Sykora, Peter Shcherbakov, Marie Laure Charkaluk, Ender Pehlivanoglu, Danuta Celinska-Cedro, Pedro Urruzuno
Publikováno v:
European Journal of Gastroenterology and Hepatology, 22(10), 1174-1181
There are no solid figures of the frequency of ulcer disease during childhood in Europe. We assessed its frequency and analyzed known risk factors. Patients and methods Ulcers, erosions, indications, and risk factors were recorded in all children und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af985b8f176d9746a54641de90bf78a4
http://hdl.handle.net/1887/110428
http://hdl.handle.net/1887/110428
Autor:
R. Gudkova, A Parfenov, L. Lazebnik, A. Konoplyannikov, I. Ruchkina, Oleg Knyazev, Peter Shcherbakov
Publikováno v:
Journal of Crohn's and Colitis. 8:S289
Publikováno v:
Inflammatory Bowel Diseases. 19:S56
Autor:
A I Parfenov, A. Konoplyannikov, Oleg Knyazev, Igor Khatykov, I N Ruchkina, Leonid Lazebnik, Peter Shcherbakov
Publikováno v:
Inflammatory Bowel Diseases. 19:S56
Publikováno v:
Journal of Crohn's and Colitis. 7:S183
Autor:
A. Konoplyannikov, L. Lazebnik, A Parfenov, Peter Shcherbakov, I. Ruchkina, V. Sagynbaeva, Oleg Knyazev
Publikováno v:
Journal of Crohn's and Colitis. 7:S181
risk in a UK population, and to evaluate whether changes in 5-ASA formulation increase the risk of relapse. Methods: A retrospective cohort study was conducted using a UK pharmacy dispensing database. Adults who received continuous treatment with Asa
Publikováno v:
Journal of Crohn's and Colitis. 7:S150
Publikováno v:
Journal of Crohn's and Colitis. 6:S95
Background: The recurrence rate of Crohn’s disease (CD) in the first year after diagnosis is 44%. Aim: to assess the impact of culture mesenchymal stromal cells (MSCs) in patients with newly diagnosed CD for the duration of disease remission. Metho
Autor:
Peter Shcherbakov, I N Ruchkina, Oleg Knyazev, A I Parfenov, A. Konoplyannikov, Leonid Lazebnik
Publikováno v:
Inflammatory Bowel Diseases. 17:S49
Publikováno v:
Gastroenterology. 140:S-318